Description:
The 2024 Maryland Legislative Session concluded with the approval of HB0127, which established the Non-Occupational Post-Exposure Prophylaxis (nPEP) Standing Order Program (“The Program”). The Program authorizes pharmacists to dispense nPEP under certain circumstances. This module presents to pharmacists the clinical and administrative tasks necessary to prescribe and/or dispense nPEP under a standing order when requested.
Release Date: October 1, 2024
Expiration Date: October 1, 2025
Target Audience
This activity is intended for physicians, pharmacists, registered nurses, PAs, psychologists, social workers and other healthcare providers engaged in the care of patients with HIV.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss HIV epidemiology locally and nationally
- Describe HIV prevention using nPEP treatment options
- Describe Maryland’s nPEP Standing Order Program
- Explain the pharmacist’s role in the Program
- Describe the process and protocol for the Program
- Discuss the management of sexual assault survivors
- Recall the funding options for patients who receive nPEP
- Describe additional resources for pharmacists registered for the Program
Faculty
Misty Carney, B.S., PharmD, AAHIVP
Prevention and Health Promotion Administration
Infectious Disease Prevention and Health Services Bureau
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
The faculty presenter has nothing to disclose.
The PIM planners and others have nothing to disclose. The HealthHIV planners and others have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthHIV. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0. 1 CEUs) of the Accreditation Council for Pharmacy Education.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.